A Phase 1b/2, Multi-Centered, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Microbiological Activity of a Single Dose of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized with Pseudomonas aeruginosa
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Bacteriophage therapeutics-BiomX (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms PHASE
- 18 Mar 2024 According to a BiomX media release, Adaptive Phage Therapeutics has been acquired and merged into BiomX
- 11 Nov 2021 New trial record
- 02 Nov 2021 According to Adaptive Phage Therapeutics media release, company entered into an agreement with the Antibacterial Resistance Leadership Group (ARLG) to support